Does Aimovig Interact with Botox for Migraines?
No known drug interactions exist between Aimovig (erenumab-aooe) and Botox (onabotulinumtoxinA) when used for migraine prevention. Aimovig, a CGRP receptor blocker given monthly by injection, and Botox, injected every 12 weeks into head and neck muscles, target different migraine pathways without overlapping metabolic or pharmacological effects. Clinical guidelines and databases like Drugs.com list no interactions for this combination.[1][2]
What Do Prescribers and Trials Say?
Real-world use often combines them safely, as both are FDA-approved for chronic migraine (≥15 headache days/month). Phase 3 trials for Aimovig excluded Botox users but reported no issues post-approval. Neurologists frequently co-prescribe without dose adjustments, per American Headache Society recommendations.[3][4]
Could Indirect Effects Happen?
Rare patient reports mention worsened headaches or injection-site reactions when starting both, but these tie to individual migraine flares, not true interactions. No evidence of reduced efficacy or increased toxicity; monitor for additive side effects like neck pain from Botox.[1][5]
Who Makes Them and Any Patent Overlaps?
Amgen manufactures Aimovig (U.S. patents expire 2033–2035).[6] Allergan (AbbVie) produces Botox for migraines (patents extend to 2030s). No shared patents or manufacturing conflicts affect co-use.
Alternatives if Concerned
If avoiding combos, options include Emgality (another CGRP blocker, no Botox interactions), Nurtec (acute + preventive CGRP), or topiramate. Consult a doctor for personalized switches.[2]
Sources
[1]: Drugs.com - Aimovig Interactions
[2]: Drugs.com - Botox Interactions
[3]: American Headache Society Guidelines
[4]: Aimovig Prescribing Information
[5]: FDA Adverse Event Reporting System (FAERS) Summary
[6]: DrugPatentWatch.com - Aimovig Patents